# NAC for Attenuation of COVID-19 Symptomatology

> **NCT05074121** · PHASE2 · UNKNOWN · sponsor: **Cambridge Health Alliance** · enrollment: 200 (estimated)

## Conditions studied

- Covid19
- COVID-19 Pneumonia
- COVID-19 Respiratory Infection
- COVID-19 Lower Respiratory Infection
- SARS-CoV2 Infection
- SARS-CoV-2 Acute Respiratory Disease
- SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
- Oxidative Stress

## Interventions

- **DRUG:** N-acetylcysteine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05074121
- **Lead sponsor:** Cambridge Health Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-31
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-02-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-08-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05074121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05074121, "NAC for Attenuation of COVID-19 Symptomatology". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05074121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*